CClinicalTrials.gg
RecruitingNCT05613049Updated Mar 27, 2025

Confounding Factors of Chronic Endometritis in Women With Reproductive Failure

An observational study in IVF, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by Chinese University of Hong Kong · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
720
Ages
20 Years to 45 Years
Sex
Female
01

Study summary

The aim of the study is to investigate the confounding factors of chronic endometritis and therapeutic benefits of antibodies targeting plasma cells in women with reproductive failure.

Read the detailed description

Eligible women, based on the inclusion and exclusion criteria, will be recruited from the IVF and/ or miscarriage clinic in the Prince of Wales Hospital/ CUHK medical centre (CUMC). Endometrial sampling (ES) will alternatively be conducted during mid-luteal phase. In natural cycles, all the subjects will have a daily urine test from day 9 of the menstrual cycle to identify the Luteinizing Hormone (LH) surge. The ES will be obtained precisely 7 days after LH surge. In artificial cycles, 6mg estradiol will be given daily orally from day 2 of the menstrual cycle for 14+/-1-2 days. Transvaginal ultrasound will be performed on day 14 of the estrogen therapy to assess the endometrial thickness and to exclude ovarian activity. If endometrial thickness is ≥8 mm, plasma progesterone level is \< 4nmol/L, progesterone will be commenced using either Endometrin (Ferring, Saint-Prex, Switzerland) 100 mg TDS vaginally. ES will be obtained using a Pipelle sampler as an outpatient procedure. The ES will be obtained precisely 5 days after progesterone supplementation.

Immunohistochemical staining will be used to determine plasma cells by using a mouse antihuman monoclonal primary anti-CD138 antibody and anti-CD38 antibody. The total number of plasma cell present in the stroma of the entire specimen will be determined and expressed as plasma cell count per unit area of the specimen. If CE is present, antibiotics will be given following the guideline from the Hospital Authority (HA). Then ES will be taken again to be re-examined by histology and microbiology.

02

Conditions studied

  • IVF

Browse trials for

Keywords

  • chronic endometritis
  • confounding factors
  • reproductive failure
  • infertility
  • IVF
  • infertility women
03

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects will be identified and recruited from the IVF and miscarriage clinic by clinicians and research nurse.

Inclusion criteria

  1. Age 20-45 years;
  2. Women with a history of 2 or more consecutive miscarriages before 24 weeks of gestation12; or
  3. Women who failed to conceive after unprotected intercourse for one year; or
  4. Women who failed failure to achieve a clinical pregnancy after two consecutive cycles of IVF, ICSI or frozen embryo replacement cycles where the cumulative number of transferred embryos is no less than four for day-2 embryos and no less than 2 for day-5 embryos (blastocysts), with all embryos being of good quality.

Exclusion criteria

Exclusion criteria

  1. Uncorrected uterine anomalies, such as the septate or bicornuate uterus, fibroids (submucous/intramural);
  2. Untreated hydrosalpinx;
  3. History of antiphospholipid syndrome;
  4. Known clinical autoimmune disease;
  5. Undergoing immunotherapy;
  6. Abnormal thyroid function;
  7. Abnormal karyotyping.
  8. Those with active pelvic inflammatory disease or suspicion of infection etc.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
720 participants (estimated)
Patient registry
No
Biospecimen retention
None retained

Groups and cohorts

  • Observational group

    Patients have 2 or more miscarriage or repeated implantation failure (RIF), or infertile women would be invited to do endometrial sampling (ES) procedure. The ES will be conducted randomly or when women undergo hysteroscopy or obtained precisely 7 days after LH surge. It will be obtained using a Pipelle sampler as an outpatient procedure.

05

What researchers measure

Primary outcomes

  1. Live birth rate

    compare the brith rate between the group and cohort

    Time frame: 31 December 2027

Secondary outcomes

  1. Compare the pregnancy rate between groups

    compare the general pregnancy rate in women with or without CE

    Time frame: 31 March 2028

  2. Compare the miscarriage rate between groups

    compare the miscarriage rate in women with or without CE

    Time frame: 31 March 2028

  3. Compare the implantation rate between groups

    Compare the implantation successful rate in women with or without CE

    Time frame: 31 March 2028

06

Study locations

1 of 1 sites recruiting
  • The Chinese University of Hong Kong
    Hong Kong, Hong Kong
    • PUI WAH JACQUELINE CHUNG, MBBS · Contact · jacquelinechung@cuhk.edu.hk · +852 35051537
    • Stacey Wong, Bsc · Contact · staceywong@cuhk.edu.hk · +852 35051764
    • PUI WAH JACQUELINE CHUNG, MBBS · Principal investigator
    • NGA PING PATRICIA IP, MBBS · Sub investigator
    • KAREN NG, MBBS · Sub investigator
    • CHI CHIU RONALD WANG, MBBS · Sub investigator
    • TAO ZHANG, MBBS · Sub investigator
    • JING XI JOSHUA LI, MBBS · Sub investigator
    • LAI PING CHEUNG, MBBS · Sub investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05613049
Lead sponsor
Chinese University of Hong Kong
Responsible party
Chung Pui Wah Jacqueline (Associate Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Nov 14, 2022
Start date
Jan 26, 2023
Primary completion
Jul 31, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Mar 27, 2025

Study contacts

Stacey Wong, BSc
Contact
staceywong@cuhk.edu.hk
35051764
JacquelinePui Wah Chung, MBBS
Contact
jacquelinechung@cuhk.edu.hk
35051764
Jacqueline Pui Wah Chung, MBBS
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion